Alimemazine

Alimemazine
Systematic (IUPAC) name
N,N,2-trimethyl-3-phenothiazin-10-yl-propan-1-amine
Clinical data
AHFS/Drugs.com International Drug Names
  • AU: C
Oral
Pharmacokinetic data
Metabolism Hepatic
Half-life 4.78 ± 0.59 hours[1]
Identifiers
84-96-8 Yes
R06AD01
PubChem CID 5574
DrugBank DB01246 Yes
ChemSpider 5373 Yes
UNII 76H78MJJ52 Yes
KEGG D07125 Yes
ChEMBL CHEMBL829 Yes
Chemical data
Formula C18H22N2S
298.447 g/mol
 Yes (what is this?)  (verify)

Alimemazine (INN), also known as trimeprazine (USAN and former BAN); brand names Nedeltran, Panectyl, Repeltin, Therafene, Theraligene, Theralen, Theralene, Vallergan, Vanectyl, and Temaril), commonly provided as a tartrate salt, is a phenothiazine derivative that is used as an antipruritic (it prevents itching from causes such as eczema or poison ivy, by acting as an antihistamine).[2] It also acts as a sedative, hypnotic, and antiemetic for prevention of motion sickness. Although it is structurally related to drugs such as chlorpromazine, it is not used as an antipsychotic.[3] In the Russian Federation, it is marketed under the brand name Teraligen for the treatment of anxiety disorders (including GAD), organic mood disorders, sleep disturbances, personality disorders accompanied by asthenia and depression, somatoform autonomic dysfunction and various neuroses.[4]

Alimemazine is not approved for use in humans in the United States. The combination of alimemazine and prednisolone (commonly sold under the brand name Temaril-P is licensed as an antipruritic and antitussive in dogs.

References

  1. ↑ Hu OY, Gfeller E, Perrin JH, Curry SH (March 1986). "Relative bioavailability of trimeprazine tablets investigated in man using HPLC with electrochemical detection". The Journal of Pharmacy and Pharmacology 38 (3): 172–6. doi:10.1111/j.2042-7158.1986.tb04539.x. PMID 2871150.
  2. ↑ "PubChem CID 78032".
  3. ↑ "Drugbank:Trimeprazine".
  4. ↑ "Russian Register of Medicines: “Teraligen” film-coated tablets (alimemazine tartrate) Patient Information Leaflet (in Russian). Revised September 2013.".